AIM ImmunoTech Inc
ASE:AIM 2:55:49 PM EDT
Earnings Announcements
Aim Immunotech Inc - As Of December 31, 2021, Aim Reported Cash And Cash Equivalents Of $48.3 Million, Compared To $54.4 Million As Of December 31, 2020
Published: 03/31/2022 20:57 GMT
AIM ImmunoTech Inc (AIM) - Aim Immunotech Inc - As of December 31, 2021, Aim Reported Cash and Cash Equivalents of $48.3 Million, Compared to $54.4 Million As of December 31, 2020.
Aim Immunotech Inc - Cash Expected to Fund Operations and Clinical Development Programs Through 2023.
Aim Immunotech Inc - Cash Expected to Fund Operations and Clinical Development Programs Through 2023.
Revenue is expected to be $0.14 Million
Adjusted EPS is expected to be -$0.08
Next Quarter Revenue Guidance is expected to be $0.15 Million
Next Quarter EPS Guidance is expected to be -$0.08
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.08
Next Quarter Revenue Guidance is expected to be $0.15 Million
Next Quarter EPS Guidance is expected to be -$0.08
More details on our Analysts Page.